allergic conjunctivitis

Ketorolac (Acuvail) is a non-steroidal anti-inflammatory drug (NSAID) in the family of heterocyclic acetic acid derivatives. It acts by inhibiting the bodily synthesis of prostaglandins.

Olopatadine hydrochloride (ALO4943A) is an antihistamine with mast-cell stabilizing properties used as eye drops in the treatment of ALLERGIC CONJUNCTIVITIS.

Tripelennamine hydrochloride (Pyribenzamine hydrochloride) is a histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation.

Alcaftadine (Lastacaft) is an H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.

Epinastine hydrochloride (WAL-801CL HCl) is an antihistamine and mast cell stabilizer that is used in eye drops to treat allergic conjunctivitis.

Astemizole (Laridal) is a synthetic piperidinyl-benzimidazol derivative with antiallergic properties, acts as a reversible competitive inhibitor of histamine H1 receptors, with less anticholinergic effects compared to related agents. It is a long-acting, non-sedative antihistaminic used in the treatment of seasonal allergic rhinitis, asthma, allergic conjunctivitis, and chronic idiopathic urticaria.

Olopatadine, an antihistamine, as well as anticholinergic and mast cell stabilizer, is used for the treatment of itching associated with allergic conjunctivitis (eye allergies). There is also a potential for Olopatadine to treat steroid rebound (red skin

Emedastine (LY188695) is a second generation, selective histamine H1 receptor antagonist with anti-allergic activity. Emedastine reversibly and competitively blocks histamine by binding to H1 receptors, thus blocking its downstream activity. As a result this agent interferes with mediator release from mast cells either by inhibiting calcium ion influx across mast cell basophil plasma membrane or by inhibiting intracellular calcium ion release within the cells. In addition, emedastine may also inhibit the late-phase allergic reaction mediated through leukotrienes or prostaglandins, or by producing an anti-platelet activating factor effect. Upon ocular administration, emedastine causes a dose-dependent inhibition of histamine-stimulated vascular permeability in the conjunctiva. Emedastine does not affect adrenergic, dopamine, or serotonin receptors.

Dexchlorpheniramine Maleate, a histamine receptor antagonist, is used to treat urticaria, allergic rhinitis, allergic conjunctivitis and pruritus.

Mapracorat (ZK-245186, BOL-303242X) is a selective glucocorticoid receptor agonist commonly used as an anti-inflammatory agent for atopic dermatitis, post-cataract surgery inflammation, and allergic conjunctivitis.

Apafant (WEB 2086) is a highly potent platelet activating factor (PAF) antagonist that blocks eosinophil activation and can be used to study experimental allergic conjunctivitis in guinea pigs.

Lodoxamide tromethamine is a mast cell stabilizer with anti-allergic properties and can be used in studies about the treatment of asthma and allergic conjunctivitis.

Ketorolac (RS37619) hydrochloride is a nonsteroidal anti-inflammatory drug and a non-selective COX inhibitor, exhibiting IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This compound is utilized in a 0.5% ophthalmic solution format for the investigation of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and post-operative ocular inflammation pain. Additionally, Ketorolac hydrochloride serves as a DDX3 inhibitor, making it pertinent for research in cancer therapies.

Carbinoxamine, an anticholinergic and antihistamine agent, is used for hay fever, angioedema, vasomotor rhinitis, mild urticaria, dermatographism and allergic conjunctivitis. It is a histamine antagonist, specifically an H1-antagonist.

Emedastine Difumarate is a selective histamine H1 receptor antagonist with anti-allergic activity, prescribed for allergic conjunctivitis. Upon ocular administration, emedastine causes a dose-dependent inhibition of histamine-stimulated vascular permeabil

Alcaftadine is a novel antihistamine for preventing allergic conjunctivitis.

Levocarbastine is a second-generation H1 receptor antagonist for allergic conjunctivitis. It also acts as a potent selective antagonist for the neurotensin receptor NTS2 and is the first drug to be used to characterize different neurotensin subtypes.

Thonzylamine (neohetramine) is an antihistamine and anticholinergic drug. It is available as combination products with Clofedanol or Phenylephrine for temporary relief of symptoms of common cold, hay fever (allergic rhinitis) or other upper respiratory allergies.

Lodoxamide (Lodoxamidum) is an antiallergic drug acting as a mast-cell stabilizer. It is effective in the treatment of asthma and allergic conjunctivitis.

Tripelennamine, an ethylenediamine derivative, acts as a potent histamine H1-receptor antagonist, effectively reducing the organism's allergic response to histamine. It is utilized in researching conditions such as rhinitis, conjunctivitis, and allergic and anaphylactic reactions [1] [2] [3].

Ketorolac (RS37619) hemicalcium is a nonselective COX inhibitor with IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This non-steroidal anti-inflammatory drug (NSAID) is used as a 0.5% ophthalmic solution for researching allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Additionally, it is a DDX3 inhibitor applicable in cancer research [1] [4].

Chloropyramine is a competitive reversible H1 receptor antagonist that can be used in allergic conditions research, for example, conjunctivitis and bronchial asthma. Chloropyramine also shows anti-tumour activity in breast cancer [1] [2].

Tripelennamine citrate is an ethylenediamine derivative and is a potent histamine H1 receptor antagonist. tripelennamine citrate reduces histamine-induced allergic reactions in the body. tripelennamine citrate can be used to study rhinitis, conjunctivitis, allergic and anaphylactic reactions.

Lirentelimab (AK002) is a humanized anti-sialic acid-binding immunoglobulin-like lectin-8 (Siglec-8) antibody that induces apoptosis of IL-5-activated eosinophils and inhibits IL-5-mediated mast cell activation, and is used in the study of refractory inert systemic mastocytosis and allergic conjunctivitis.